A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : HMBA / hexamethylene bisacetamide

[Related PubMed/MEDLINE]
Total Number of Papers: 376
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   HMBA  (>> Co-occurring Abbreviation)
Long Form:   hexamethylene bisacetamide
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2019 Alternate NF-kappaB-Independent Signaling Reactivation of Latent HIV-1 Provirus. ASA, cART, IKKbeta, LRAs, LTR, TCM
2019 Hexamethylene bisacetamide impairs NK cell-mediated clearance of acute T lymphoblastic leukemia cells and HIV-1-infected T cells that exit viral latency. NK, PRO, T-ALL
2019 Inhibition of the histone demethylase, KDM5B, directly induces re-expression of tumor suppressor protein HEXIM1 in cancer cells. ---
2017 Anti-Cancer Drug HMBA Acts as an Adjuvant during Intracellular Bacterial Infections by Inducing Type I IFN through STING. ---
2017 HMBA is a putative HSP70 activator stimulating HEXIM1 expression that is down-regulated by estrogen. HEXIM1, HSP70
2016 A Subset of Latency-Reversing Agents Expose HIV-Infected Resting CD4+ T-Cells to Recognition by Cytotoxic T-Lymphocytes. ART, LRAs
2016 Cancer Differentiating Agent Hexamethylene Bisacetamide Inhibits BET Bromodomain Proteins. ---
2016 HMBA Enhances Prostratin-Induced Activation of Latent HIV-1 via Suppressing the Expression of Negative Feedback Regulator A20/TNFAIP3 in NF-kappaB Signaling. ---
2016 Induction of HEXIM1 activities by HMBA derivative 4a1: Functional consequences and mechanism. ---
10  2016 Toxicity and in vitro activity of HIV-1 latency-reversing agents in primary CNS cells. cART, CNS, LRA, PFA
11  2015 Transcriptome analysis of a CHO cell line expressing a recombinant therapeutic protein treated with inducers of protein expression. CHO, DHFR, GSEA
12  2014 Brd4 and HEXIM1: multiple roles in P-TEFb regulation and cancer. Brd4, P-TEFb
13  2014 Lead optimization of HMBA to develop potent HEXIM1 inducers. HEXIM1
14  2013 Bovine HEXIM1 inhibits bovine immunodeficiency virus replication through regulating BTat-mediated transactivation. B-cyclin T1, BIV
15  2013 Enhancement of baicalin by hexamethylenebisacetamide on the induction of apoptosis contributes to simultaneous activation of the intrinsic and extrinsic apoptotic pathways in human leukemia cells. AML
16  2013 Identification of KAP-1-associated complexes negatively regulating the Ey and beta-major globin genes in the beta-globin locus. MEL
17  2013 Sphingosine kinase 1 expression is downregulated during differentiation of Friend cells due to decreased c-MYB. SphK1
18  2012 7SK snRNA: a noncoding RNA that plays a major role in regulating eukaryotic transcription. hnRNPs, La, MePCE, P-TEFb, RNAPII, RNAPIII, snRNA, snRNP
19  2012 Bis-pyrrolyl-tetrazolyl derivatives as hybrid polar compounds: A case of lipophilic functional bioisosterism with bis-acetamides. MEL
20  2012 Bromodomain and extra-terminal (BET) bromodomain inhibition activate transcription via transient release of positive transcription elongation factor b (P-TEFb) from 7SK small nuclear ribonucleoprotein. BET, P-TEFb, SAHA, SEC
21  2012 Latent HIV-1 infection occurs in multiple subsets of hematopoietic progenitor cells and is reversed by NF-kappaB activation. HPCs, P-TEFb, SAHA, TNF-alpha
22  2012 Selected drugs with reported secondary cell-differentiating capacity prime latent HIV-1 infection for reactivation. HDAC, SAHA
23  2011 CD99/MIC2 Constitutes a Differentiation Antigen of a Human Osteoblast Cell Line. ALP, EFT, HDAC
24  2011 Cholesterol esterification during differentiation of mouse erythroleukemia (Friend) cells. ACAT
25  2011 Determination of hexamethylene bisacetamide, an antineoplastic compound, in mouse and human plasma by LC-MS/MS. FDA, HEXIM1
26  2011 P27(Kip1), regulated by glycogen synthase kinase-3beta, results in HMBA-induced differentiation of human gastric cancer cells. ---
27  2010 Aberrant expression of nuclear matrix proteins during HMBA-induced differentiation of gastric cancer cells. ---
28  2010 Localization and altered expression of nucleophosmin in the nuclear matrix during the differentiation of human hepatocarcinoma SMMC-7721 cells induced by HMBA. ---
29  2009 A potential novel combination therapy targeting survivin in renal cancer cells: Inhibition of survivin expression by topotecan and hexamethylene bisacetamide. ---
30  2009 Bioreducible hyperbranched poly(amido amine)s for gene delivery. CBA, DMDPTA, RHB
31  2009 Hexamethylene bisacetamide can convert nonpermissive human cells to a permissive state for expressing the major immediate-early genes of human cytomegalovirus by up-regulating NF-kappaB activity. HCMV, MIE, MIEP
32  2009 Spi-1 and Fli-1 directly activate common target genes involved in ribosome biogenesis in Friend erythroleukemic cells. ---
33  2008 Discordant varicella-zoster virus glycoprotein C expression and localization between cultured cells and human skin vesicles. VZV
34  2008 Effect of hexamethylene bisacetamide (HMBA) on the microtubular system of Tetrahymena pyriformis. ---
35  2008 Hexamethylbisacetamide and disruption of human immunodeficiency virus type 1 latency in CD4(+) T cells. ART, CDK9, LTR
36  2008 Hexamethylene bisacetamide (HMBA) simultaneously targets AKT and MAPK pathway and represses NF kappaB activity: implications for cancer therapy. ---
37  2008 Hexamethylene bisacetamide inhibits malignant phenotype in T-ALL cell lines. T-ALL
38  2008 Hexamethylene bisacetamide leads to reduced helper virus-free HSV-1 amplicon expression titers via suppression of ICP0. HSV
39  2008 Positional and expressive alteration of prohibitin during the induced differentiation of human hepatocarcinoma SMMC-7721 cells. PHB
40  2008 PP2B and PP1alpha cooperatively disrupt 7SK snRNP to release P-TEFb for transcription in response to Ca2+ signaling. P-TEFb, PP1alpha, PP2B
41  2008 Relationship between the induction of leukemia cell differentiation and the enhancement of reporter gene expression in 3T3 Swiss cells. HDAC, TSA
42  2008 [Expression and localization of hnRNP A2/B1 during differentiation of human osteosarcoma MG-63 cells induced by HMBA]. LSCM
43  2008 [Molecular mechanism underlying differentiation of HL-60 cells induced by hexamethylene bisacetamide]. ---
44  2007 Alteration of nuclear matrix-intermediate filament system and differential expression of nuclear matrix proteins during human hepatocarcinoma cell differentiation. IF, MALDI-TOF MS, NM, NM-IF
45  2007 Down-regulation of CD44 contributes to the differentiation of HL-60 cells induced by ATRA or HMBA. AML, ATRA
46  2007 HEXIM1 and the control of transcription elongation: from cancer and inflammation to AIDS and cardiac hypertrophy. HEXIM1, P-TEFb, VSMCs
47  2007 HMBA releases P-TEFb from HEXIM1 and 7SK snRNA via PI3K/Akt and activates HIV transcription. P-TEFb, snRNA
48  2007 Human pluripotent embryonal carcinoma NTERA2 cl.D1 cells maintain their typical morphology in an angiomyogenic medium. BMP, BMP2, RA
49  2007 Subcellular transport of EKLF and switch-on of murine adult beta maj globin gene transcription. DMSO, EKLF, MEL
50  2007 Tat competes with HEXIM1 to increase the active pool of P-TEFb for HIV-1 transcription. CDK9, HIV-1, P-TEFb, snRNA, snRNP, Tat
51  2007 Temporal variation in the expression of the p53 protein in proliferating and differentiating murine erythroleukaemia cells. MEL
52  2006 1,6-Diaminohexane contributes to the hexamethylene bisacetamide-induced erythroid differentiation pathway by stimulating Ca2+ release from inositol 1,4,5-trisphosphate-sensitive stores and promoting Ca2+ influx. DAH, MEL, NADAH
53  2006 Changes of nuclear matrix proteins following the differentiation of human osteosarcoma MG-63 cells. NMPs
54  2006 Delayed biosynthesis of varicella-zoster virus glycoprotein C: upregulation by hexamethylene bisacetamide and retinoic acid treatment of infected cells. hpi, VZV
55  2006 Enhancement of antitumor activity of herpes simplex virus gamma(1)34.5-deficient mutant for oral squamous cell carcinoma cells by hexamethylene bisacetamide. HSV-1, MOI, SCC
56  2006 Hexamethylbisacetamide remodels the human immunodeficiency virus type 1 (HIV-1) promoter and induces Tat-independent HIV-1 expression but blunts cell activation. HIV-1, LTR, Nuc-1, PBMC
57  2006 Increased HEXIM1 expression during erythroleukemia and neuroblastoma cell differentiation. ---
58  2006 Modulation of a P-TEFb functional equilibrium for the global control of cell growth and differentiation. MELC
59  2006 The carbonic anhydrase I locus contains a c-Myb target promoter and modulates differentiation of murine erythroleukemia cells. CAI, CAIe
60  2006 [Changes of nuclear matrix proteins during differentiation of human osteosarcoma MG-63 cells induced by HMBA]. ---
61  2005 Altered profiles of nuclear matrix proteins during the differentiation of human gastric mucous adenocarcinoma MGc80-3 cells. MALDI-TOF MS
62  2005 Inhibitory effect of hexamethylene bisacetamide on replication of human cytomegalovirus. HCMV, HEL, IE2
63  2005 Interplay between 7SK snRNA and oppositely charged regions in HEXIM1 direct the inhibition of P-TEFb. 7SK snRNA, P-TEFb
64  2005 Temporal changes in the expression of protein phosphatase 1 and protein phosphatase 2A in proliferating and differentiating murine erythroleukaemia cells. MEL, PP1, PP2A
65  2004 Activation of transiently transfected reporter genes in 3T3 Swiss cells by the inducers of differentiation/apoptosis--dimethylsulfoxide, hexamethylene bisacetamide and trichostatin A. HDACs, TSA
66  2004 Applying proteomic methodologies to analyze the effect of hexamethylene bisacetamide (HMBA) on proliferation and differentiation of human gastric carcinoma BGC-823 cells. RFPL1, RGS1
67  2004 Differentiation-dependent photodynamic therapy regulated by porphobilinogen deaminase in B16 melanoma. ALA, PBGD, PpIX
68  2004 Growth arrest and apoptosis of human hepatocellular carcinoma cells induced by hexamethylene bisacetamide. ---
69  2004 HMBA induces cell death and potentiates doxorubicin toxicity in malignant mesothelioma cells. DOX, MM
70  2004 [Effect of HMBA on differentiation and apoptosis of HL-60 and U937 cells and its mechanism]. ---
71  2003 Clinical and laboratory studies of expression of cyclin A in leukemia cells. ---
72  2003 Differential expression of Ran GTPase during HMBA-induced differentiation in murine erythroleukemia cells. MEL
73  2003 Induction of apoptosis by combined treatment with differentiation-inducing agents and interferon-alpha in human lung cancer cells. DMSO, IFN
74  2003 Overexpression of the immediate early gene fra-1 inhibits proliferation, induces apoptosis, and reduces tumourigenicity of c6 glioma cells. dbcAMP
75  2003 The cleavage product deltaPML-RARalpha contributes to all-trans retinoic acid-mediated differentiation in acute promyelocytic leukemia cells. ATRA
76  2003 [Effects of hexamethylene bisacetamide on cell cycle and expression of its regulatory proteins in HL-60 cells]. ---
77  2002 A Myb dependent pathway maintains Friend murine erythroleukemia cells in an immature and proliferating state. MEL, MEnT
78  2002 Membrane phospholipid reorganization differentially regulates metallothionein and heme oxygenase by heme-hemopexin. DSC, HO-1, HPX, MT-I, PKC
79  2002 Specific PAF antagonist WEB-2086 induces terminal differentiation of murine and human leukemia cells. MELCs
80  2002 Targeted removal of PML-RARalpha protein is required prior to inhibition of histone deacetylase for overcoming all-trans retinoic acid differentiation resistance in acute promyelocytic leukemia. AcH3, HDACi, tRA
81  2002 [Effect of hexamethylene bisacetamine on proliferation and apoptosis of human leukemia cells in vitro and relevant mechanisms]. FITC
82  2002 [Effects of hexamethylene bisacetamide on related genes expression of apoptosis and cell proliferating in human mucoepidermoid carcinoma cell line MEC-1]. ---
83  2001 A novel system to identify Myb target promoters in friend murine erythroleukemia cells. MEL, MEnT, MTH
84  2001 Hexamethylene bisacetamide protects peritoneal mesothelial cells from glucose. Cx43, GJIC, HPMCs, MAPK, PKC
85  2001 Regulation of tyrosinase-related protein-2 (TYRP2) in human melanocytes: relationship to growth and morphology. MITF, TPA, TYR, TYRP2
86  2001 Structural characterization of erythroid and megakaryocytic differentiation in Friend erythroleukemia cells. ---
87  2001 [Regulation of Chinese medicine bailong and hexamethylene bisacetamide on cyclin dependent kinase inhibitor P16 genes in human cancer cell]. CKI-P16
88  2001 [Regulative effects of bailong and Hexamethylene bisacetamide on growth and phenotype of human gastric cancer cells in cell cycle]. ---
89  2001 [Study on common character of regulative molecular mechanism of Chinese drug bailong and hexamethylen bisacetamide in human cancer cell cycle and their oncogene and tumor suppressor gene expression]. ---
90  2000 A transient dephosphorylation of JAK1 and JAK2 characterises the early-phase response of murine erythroleukemia cells to the differentiation inducer hexamethylenebisacetamide. HPC, MELC
91  2000 Association between the calcium-binding protein calretinin and cytoskeletal components in the human colon adenocarcinoma cell line WiDr. CR
92  2000 Equivalent death of P-glycoprotein expressing and nonexpressing cells induced by the protein kinase C inhibitor staurosporine. P-gp
93  2000 Expression and Up-regulation of alternatively spliced transcripts of melastatin, a melanoma metastasis-related gene, in human melanoma cells. ---
94  2000 HMBA induces activation of a caspase-independent cell death pathway to overcome P-glycoprotein-mediated multidrug resistance. MDR, P-gp
95  2000 Hybrid polar compounds produce a positive shift in the surface dipole potential of self-assembled phospholipid monolayers. HPCs, MELCs, SAHA
96  2000 Induction of apoptosis by hexamethylene bisacetamide is p53-dependent associated with telomerase activity but not with terminal differentiation. ---
97  2000 Modest increases in the titers of helper virus-free herpes simplex virus 1 (HSV-1) vectors by packaging in a cell line with inducible expression of HSV-1 VP16 or by treatment with N,N'-hexamethylene-bis-acetamide. HSV-1, IE
98  2000 Rhythmic patterns in the expression of the ras oncogene in proliferating and differentiating erythroleukaemia cells. MEL
99  2000 [Effects of hexamethylene bisacetamide on in vitro adhesion, motility and invasion of human mucoepidermoid carcinoma cell line MEC-1]. ---
100  1999 Chemoprevention of carcinogen-induced mammary tumorigenesis by the hybrid polar cytodifferentiation agent, suberanilohydroxamic acid (SAHA). HPC, NMU, SAHA